Single-circulation-copy AIDS virus-like particle and preparation method and application thereof

Abstract

The invention discloses single-circulation-copy AIDS virus-like particle and a preparation method and application thereof.The virus-like particle is obtained through separation and screening after an HIV provirus plasmid with multiple genes being deleted, a CMV-Gag / Pol expression plasmid and an Env expression plasmid co-transfect cells, and the HIV provirus plasmid has the base sequence as shown in SEQ ID No.1 after the HIV provirus plasmid replaces the virus nef gene sequence for marking through a Gaussia luciferase gene sequence.The virus-like particle is used for preparing a monoclonal antibody using immune animals for diagnosing and treating, a targeting vaccine serving as a dendritic cell, and the infection source for CD4+T cell system in-vitro infection and animal AIDS virus infection.The single-circulation-copy AIDS virus-like particle is high in sensitivity, high in safety, and applicable to different labs without three-level lab closed environments.

Description

technical field [0001] The invention belongs to the technical field of virus-like particles, and in particular relates to a single-circulation replication HIV-like particle and its preparation method and application. Background technique [0002] Acquired Immunodeficiency Syndrome (AIDS) is a degenerative disease of the immune and nervous systems caused by HIV-1 infection. This infectious disease has threatened the survival, welfare and social stability of the world. Global estimates of HIV epidemiology indicate that in 2012, there were already 35.3 million HIV-1 carriers worldwide, with 2.3 million new cases that year alone. Even with the remarkable progress in the field of anti-HIV-1 chemotherapy over the past few decades, effective prevention of HIV-1 infection remains one of the most important challenges due to the rapid emergence of viral escape strains and drug resistance. Therefore, developing novel anti-HIV methods and better understanding the mechanism of latent HI...

AI Technical Summary

Problems solved by technology

However, due to the high pathogenicity of the HIV-1 virus, the precautionary facilities required to study various anti-HIV strategies must reach Biosafety Level 3 (BSL-3), and the above-mentioned experiments on HIV infection on humanized mice are also the same. It needs to be carried out in a three-level biosafety laboratory. Many scientific research teams have made great contributions to the fight against HIV, but because of the need for high-level security facilities, they are restricted from further research

Images